Search Results - "COPELAND, Amanda"

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial by Younes, Anas, Dr, Berdeja, Jesus G, MD, Patel, Manish R, MD, Flinn, Ian, MD, Gerecitano, John F, MD, Neelapu, Sattva S, MD, Kelly, Kevin R, MD, Copeland, Amanda R, MSN, Akins, Amy, BSN, Clancy, Myles S, MBA, Gong, Lucy, PharmD, Wang, Jing, PhD, Ma, Anna, MS, Viner, Jaye L, MD, Oki, Yasuhiro, MD

“…Summary Background Treatment options for patients with relapsed or refractory lymphoma and multiple myeloma are limited. CUDC-907 is an oral, first-in-class,…”
Get full text

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial by Younes, Anas, Prof, Oki, Yasuhiro, MD, Bociek, R Gregory, MD, Kuruvilla, John, MD, Fanale, Michelle, MD, Neelapu, Sattva, MD, Copeland, Amanda, RN, Buglio, Daniela, MD, Galal, Ahmed, MD, Besterman, Jeffrey, PhD, Li, Zuomei, PhD, Drouin, Michel, MD, Patterson, Tracy, RN, Ward, M Renee, MD, Paulus, Jessica K, ScD, Ji, Yuan, PhD, Medeiros, L Jeffrey, Prof, Martell, Robert E, MD

“…Summary Background The prognosis of patients with relapsed Hodgkin's lymphoma, especially those who relapse after stem-cell transplantation, is poor, and the…”
Get full text

Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma by Younes, Anas, Kim, Stella, Romaguera, Jorge, Copeland, Amanda, Farial, Silvana de Castro, Kwak, Larry W, Fayad, Luis, Hagemeister, Frederick, Fanale, Michelle, Neelapu, Sattva, Lambert, John M, Morariu-Zamfir, Rodica, Payrard, Sandrine, Gordon, Leo I

“…We determine the maximum-tolerated dose (MTD), pharmacokinetics, safety, and preliminary efficacy of SAR3419, an antibody-drug conjugate targeting CD19, in a…”
Get full text

Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes by Younes, Anas, Romaguera, Jorge, Fanale, Michelle, McLaughlin, Peter, Hagemeister, Frederick, Copeland, Amanda, Neelapu, Sattva, Kwak, Larry, Shah, Jatin, de Castro Faria, Silvana, Hart, Stefan, Wood, Jeanette, Jayaraman, Ramesh, Ethirajulu, Kantharaj, Zhu, Joy

“…The Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT) pathway plays an important role in the pathogenesis of hematologic…”
Get full text

Evaluation of US oncology electronic health record real-world data to reduce uncertainty in health technology appraisals: a retrospective cohort study by Mpofu, Philani, Kent, Seamus, Jónsson, Páll, Pittell, Harlan, Groves, Brad, Altomare, Ivy, Copeland, Amanda, Baxi, Shrujal, Bargo, Danielle, Sujenthiran, Arun, Adamson, Blythe

“…ObjectivesExamine whether data from early access to medicines in the USA can be used to inform National Institute for Health and Care Excellence (NICE) health…”
Get full text

ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma by Batlevi, Connie Lee, Kasamon, Yvette, Bociek, R Gregory, Lee, Peter, Gore, Lia, Copeland, Amanda, Sorensen, Rachel, Ordentlich, Peter, Cruickshank, Scott, Kunkel, Lori, Buglio, Daniela, Hernandez-Ilizaliturri, Francisco, Younes, Anas

“…Classical Hodgkin lymphoma treatment is evolving rapidly with high response rates from antibody-drug conjugates targeting CD30 and immune checkpoint…”
Get full text

Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma by Soumerai, Jacob D., Ni, Andy, Alperovich, Anna, Batlevi, Connie, Bantilan, Kurt S., Fischer, Thais, Copeland, Amanda R., Smith, Katy, Ying, Zhitao, Younes, Anas, Zelenetz, Andrew D.

“…It is difficult to demonstrate an overall survival (OS) benefit in trials of immediate therapy vs observation in follicular lymphoma (FL). Time to 2nd…”
Get full text

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma by Younes, Anas, Oki, Yasuhiro, McLaughlin, Peter, Copeland, Amanda R., Goy, Andre, Pro, Barbara, Feng, Lei, Yuan, Ying, Chuang, Hubert H., Macapinlac, Homer A., Hagemeister, Fredrick, Romaguera, Jorge, Samaniego, Felipe, Fanale, Michelle A., Dabaja, Bouthaina Shbib, Rodriguez, Maria A., Dang, Nam, Kwak, Larry W., Neelapu, Sattva S., Fayad, Luis E.

“…In the present study, we evaluated the efficacy and safety of rituximab in combination with standard doxorubicin, bleomycin, vinblastine, and dacarbazine…”
Get full text

Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma by Hu, Bei, Younes, Anas, Westin, Jason R., Turturro, Francesco, Claret, Linda, Feng, Lei, Fowler, Nathan, Neelapu, Sattva, Romaguera, Jorge, Hagemeister, Fredrick B., Rodriguez, Maria Alma, Samaniego, Felipe, Fayad, Luis E., Copeland, Amanda R., Nastoupil, Loretta J., Nieto, Yago, Fanale, Michelle A., Oki, Yasuhiro

“…This phase-I/phase-II study evaluated panobinostat in combination with ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory classical Hodgkin…”
Get full text

Phase II Study of Yttrium-90–Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma by WANG, Michael, OKI, Yasuhiro, SAMUELS, Barry I, LOYER, Evelyne M, YUAN JI, YOUNES, Anas, PRO, Barbara, ENRIQUE ROMAGUERA, Jorge, ALMA RODRIGUEZ, Maria, SAMANIEGO, Felipe, MCLAUGHLIN, Peter, HAGEMEISTER, Frederick, NEELAPU, Sattva, COPELAND, Amanda

“…This phase II trial evaluated the safety and efficacy of yttrium-90 ((90)Y)-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma…”
Get full text

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay by Intlekofer, Andrew M., Joffe, Erel, Batlevi, Connie L., Hilden, Patrick, He, Jie, Seshan, Venkatraman E., Zelenetz, Andrew D., Palomba, M. Lia, Moskowitz, Craig H., Portlock, Carol, Straus, David J., Noy, Ariela, Horwitz, Steven M., Gerecitano, John F., Moskowitz, Alison, Hamlin, Paul, Matasar, Matthew J, Kumar, Anita, van den Brink, Marcel R., Knapp, Kristina M., Pichardo, Janine D., Nahas, Michelle K., Trabucco, Sally E., Mughal, Tariq, Copeland, Amanda R., Papaemmanuil, Elli, Moarii, Mathai, Levine, Ross L., Dogan, Ahmet, Miller, Vincent A., Younes, Anas

“…We sought to define the genomic landscape of diffuse large B-cell lymphoma (DLBCL) by using formalin-fixed paraffin-embedded (FFPE) biopsy specimens. We used…”
Get full text

Alcohol-Based Handrub Formulated Developed Specifically for High-use Environments Can Improve Key Skin Condition Measures While Maintaining Aesthetics and Antimicrobial Efficacy by Copeland, Amanda J, Cartner, Todd, Edmonds, Sarah L., MS, Tian, Kegui

“…Use of electronic-compliance-monitoring (ECM) systems has shown that hand-hygiene compliance (HHC) measured by visual observation is significantly…”
Get full text

Phase II Study of an AKT Inhibitor MK2206 in Patients with Relapsed or Refractory Lymphoma by Oki, Yasuhiro, Fanale, Michelle A., Romaguera, Jorge E., Fayad, Luis, Fowler, Nathan, Copeland, Amanda R.M., Samaniego, Felipe, Kwak, Larry W., Neelapu, Sattva S, Wang, Michael, Feng, Lei, Younes, Anas

“…Aberrant activation of the PI3K/AKT/mTOR pathway has been implicated in promoting lymphoma cell growth and survival. Several agents targeting this pathway at…”
Get full text

Identification of Actionable Genomic Alterations Across Different Lymphoma Histologies Using a Comprehensive Next Generation Genomic Sequencing Clinical Assay by Batlevi, Connie, Moskowitz, Craig H., Zelenetz, Andrew D., Horwitz, Steven M., Palomba, Lia, Gerecitano, John F., Copeland, Amanda R.M., Hamlin, Paul, Matasar, Matthew J., Sauter, Craig S., Moskowitz, Alison J, Noy, Ariela, Straus, David J., Portlock, Carol S, Mazzei, Colleen, Pichardo, Janine D., Miller, Vincent, Stephens, Phil J, He, Jie, Feldstein, Julie T, Levine, Ross L., Dogan, Ahmet, Younes, Anas

“…Background: Several retrospective series have characterized the genomic landscape in many lymphoma subtypes. However, as these studies used different…”
Get full text

Profiling Genomic Alterations Of Diffuse Large B-Cell Lymphoma (DLBCL) At Diagnosis, Relapse, and Transformation, Using a Novel Clinical Diagnostic Targeted Sequencing Platform by Intlekofer, Andrew M., Sheshan, Venkatraman E., Levine, Ross L., Zelenetz, Andrew D., Teruya-Feldstein, Julie, Dogan, Ahmet, Palomba, Maria Lia, Moskowitz, Craig H., van den Brink, Marcel R.M., Knapp, Kristina M., Copeland, Amanda R.M., Pichardo, Janine D., Brennan, Kristina W., Young, Geneva, He, Jie, Nahas, Michelle K., Yelensky, Roman, Otto, Geoff A., Lipson, Doron, Stephens, Philip J., Miller, Vincent A., Younes, Anas

“…Whole genome and exome sequencing studies have identified numerous genomic alterations in DLBCL, but these methods have limited applicability for the clinical…”
Get full text

Current treatment strategies in Hodgkin lymphomas by Copeland, Amanda, Younes, Anas

“…PURPOSE OF REVIEWThis review will focus on monoclonal antibodies and small molecule inhibitors used in the treatment of newly diagnosed and relapsed/refractory…”
Get full text

Novel Non-Antimicrobial Soap Developed to Improve Skin Cleansing for Healthcare by Copeland, Amanda, Cartner, Todd J., Rulison, Christopher

Get full text

ADS-61 - Novel Non-Antimicrobial Soap Developed to Improve Skin Cleansing for Healthcare by Copeland, Amanda, Cartner, Todd J., Rulison, Christopher

Get full text

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma by Oki, Yasuhiro, Fanale, Michelle, Romaguera, Jorge, Fayad, Luis, Fowler, Nathan, Copeland, Amanda, Samaniego, Felipe, Kwak, Larry W., Neelapu, Sattva, Wang, Michael, Feng, Lei, Younes, Anas

“…Summary We conducted a phase II study of the AKT inhibitor, MK2206 in patients with relapsed or refractory lymphoma of any histology excluding Burkitt lymphoma…”
Get full text

A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma by Batlevi, Connie L., Crump, Michael, Andreadis, Charalambos, Rizzieri, David, Assouline, Sarit E., Fox, Susan, Jagt, Richard H. C., Copeland, Amanda, Potvin, Diane, Chao, Richard, Younes, Anas

“…Summary Deregulation of histone deacetylase (HDAC) is important in the pathogenesis of follicular lymphoma (FL) and diffuse large B‐cell lymphoma (DLBCL)…”
Get full text